ArticleInternational journal of nanomedicine2017
Near-infrared light-triggered theranostics for tumor-specific enhanced multimodal imaging and photothermal therapy.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Photothermal conversion hydrogel based mini-eye patch for relieving dry eye with long-term use of the light-emitting screen.International journal of nanomedicine · 2019Trial
- An Injectable Photothermal Responsive Liposome Hydrogel Co-Loaded with Bufalin, Apatinib, and IR820 for Inhibiting Postoperative Recurrence of Colon Cancer.International journal of nanomedicine · 2026Article
- Review
- Near-Infrared Light-Activated Oxygen Generator a Multidynamic Photo-Nanoplatform for Effective Anti-Cutaneous Squamous Cell Carcinoma Treatment.International journal of nanomedicine · 2022Article
- Near-Infrared Light-Triggered Thermosensitive Liposomes Modified with Membrane Peptides for the Local Chemo/Photothermal Therapy of Melanoma.OncoTargets and therapy · 2021Article
- IR820 functionalized melanin nanoplates for dual-modal imaging and photothermal tumor eradication.Nanoscale advances · 2020Article
- Core‑shell type thermo‑nanoparticles loaded with temozolomide combined with photothermal therapy in melanoma cells.Oncology reports · 2019Article
- Nanotechnology Meets Oncology: Nanomaterials in Brain Cancer Research, Diagnosis and Therapy.Materials (Basel, Switzerland) · 2019Review
- Current Trends in Cancer Nanotheranostics: Metallic, Polymeric, and Lipid-Based Systems.Pharmaceutics · 2019Review
- Recent developments in multimodality fluorescence imaging probes.Acta pharmaceutica Sinica. B · 2018Review
- Evaluation of methotrexate-conjugated gadolinium(III) for cancer diagnosis and treatment.Drug design, development and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major challenge in current clinic contrast agents (CAs) and chemotherapy is the poor tumor selectivity and response. Based on the self-quench property of IR820 at high concentrations, and different contrast effect ability of Gd-DOTA between inner and outer of liposome, we developed "bomb-like" light-triggered CAs (LTCAs) for enhanced CT/MRI/FI multimodal imaging, which can improve the signal-to-noise ratio of tumor tissue specifically. IR820, Iohexol and Gd-chelates were firstly encapsulated into the thermal-sensitive nanocarrier with a high concentration. This will result in protection and fluorescence quenching. Then, the release of CAs was triggered by near-infrared (NIR) light laser irradiation, which will lead to fluorescence and MRI activation and enable imaging of inflammation. In vitro and in vivo experiments demonstrated that LTCAs with 808 nm laser irradiation have shorter T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.